JP2018528975A - 小児患者におけるａｄａｍｔｓ１３欠乏および先天性血栓性血小板減少性紫斑病の処置方法 - Google Patents

小児患者におけるａｄａｍｔｓ１３欠乏および先天性血栓性血小板減少性紫斑病の処置方法 Download PDF

Info

Publication number
JP2018528975A
JP2018528975A JP2018515541A JP2018515541A JP2018528975A JP 2018528975 A JP2018528975 A JP 2018528975A JP 2018515541 A JP2018515541 A JP 2018515541A JP 2018515541 A JP2018515541 A JP 2018515541A JP 2018528975 A JP2018528975 A JP 2018528975A
Authority
JP
Japan
Prior art keywords
antibody
antigen
seq
binding fragment
adamts13
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018515541A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018528975A5 (enExample
Inventor
マリーナ ノリス，
マリーナ ノリス，
カルミーネ ペコラーロ，
カルミーネ ペコラーロ，
ジュゼッペ レムッツィ，
ジュゼッペ レムッツィ，
Original Assignee
アレクシオン ファーマシューティカルズ， インコーポレイテッド
アレクシオン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクシオン ファーマシューティカルズ， インコーポレイテッド, アレクシオン ファーマシューティカルズ， インコーポレイテッド filed Critical アレクシオン ファーマシューティカルズ， インコーポレイテッド
Publication of JP2018528975A publication Critical patent/JP2018528975A/ja
Publication of JP2018528975A5 publication Critical patent/JP2018528975A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2018515541A 2015-09-28 2016-09-23 小児患者におけるａｄａｍｔｓ１３欠乏および先天性血栓性血小板減少性紫斑病の処置方法 Pending JP2018528975A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562233630P 2015-09-28 2015-09-28
US62/233,630 2015-09-28
US201562235618P 2015-10-01 2015-10-01
US62/235,618 2015-10-01
PCT/IB2016/001419 WO2017055908A1 (en) 2015-09-28 2016-09-23 Methods of treating adamts13 deficiencies and congenital thrombotic thrombocytopenia in pediatric patients

Publications (2)

Publication Number Publication Date
JP2018528975A true JP2018528975A (ja) 2018-10-04
JP2018528975A5 JP2018528975A5 (enExample) 2019-10-31

Family

ID=57200050

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018515541A Pending JP2018528975A (ja) 2015-09-28 2016-09-23 小児患者におけるａｄａｍｔｓ１３欠乏および先天性血栓性血小板減少性紫斑病の処置方法

Country Status (4)

Country Link
US (1) US20180237509A1 (enExample)
EP (1) EP3356402A1 (enExample)
JP (1) JP2018528975A (enExample)
WO (1) WO2017055908A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023549878A (ja) * 2020-11-18 2023-11-29 グリーン・クロス・コーポレイション 自己抗体に対する回避率又は活性が向上したａｄａｍｔｓ１３バリアント

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4374922A3 (en) 2016-06-14 2024-08-28 Regeneron Pharmaceuticals, Inc. Anti-c5 antibodies and uses thereof
SG11202004662RA (en) 2017-12-13 2020-06-29 Regeneron Pharma Anti-c5 antibody combinations and uses thereof
CN119019553B (zh) * 2024-09-18 2025-09-23 广州博富瑞医学检验有限公司 一种抗补体蛋白c5的抗体及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9415102B2 (en) * 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US20150166676A1 (en) * 2011-04-08 2015-06-18 Omeros Corporation Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AM. J. KIDNEY DIS., vol. 66, no. 6, JPN6020033581, 22 September 2015 (2015-09-22), pages 1067 - 1070, ISSN: 0004488242 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023549878A (ja) * 2020-11-18 2023-11-29 グリーン・クロス・コーポレイション 自己抗体に対する回避率又は活性が向上したａｄａｍｔｓ１３バリアント

Also Published As

Publication number Publication date
WO2017055908A1 (en) 2017-04-06
EP3356402A1 (en) 2018-08-08
US20180237509A1 (en) 2018-08-23

Similar Documents

Publication Publication Date Title
JP7577542B2 (ja) 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与
JP7518764B2 (ja) 発作性夜間ヘモグロビン尿症（ＰＮＨ）および非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量および投与
EP3914617B1 (en) Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus)
CA3022097A1 (en) Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
BR112020006692A2 (pt) dosagem e administração de anticorpos anti-c5 para o tratamento de pacientes com glomerulonefrite membranoproliferativa
JP6105146B2 (ja) Ｐａｎ−ＥＬＲ＋ＣＸＣケモカイン抗体
JP2023533030A (ja) 小児患者において発作性夜間血色素尿症（ｐｎｈ）を治療するための抗ｃ５抗体の投薬量及び投与
JP2018528975A (ja) 小児患者におけるａｄａｍｔｓ１３欠乏および先天性血栓性血小板減少性紫斑病の処置方法
EP4378479A2 (en) Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody
JP7127859B2 (ja) キメラタンパク質を用いたアレルギー疾患の治療
WO2019201301A1 (zh) 抗gitr抗体及其用途
AU2021326526A1 (en) Dosage and administration of anti-C5 antibodies for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA)
CN113754763A (zh) 分离的抗原结合蛋白及其用途
AU2021294687C1 (en) Antibodies specifically recognizing C5A and uses thereof
CN116178530A (zh) 抗体在治疗SARS-CoV-2感染的用途
JP2023526051A (ja) 発作性夜間ヘモグロビン尿症の処置のための補体ｄ因子阻害剤の単独又は抗ｃ５抗体との組み合わせでの使用
RU2822664C2 (ru) ДОЗЫ И ВВЕДЕНИЕ АНТИТЕЛ ПРОТИВ C5 ДЛЯ ЛЕЧЕНИЯ АТИПИЧНОГО ГЕМОЛИТИКО-УРЕМИЧЕСКОГО СИНДРОМА (аГУС)
HK40110798A (en) Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody
WO2023077230A1 (en) Products and methods for the diagnosis and treatment of heparin-induced thrombocytopenia
JP2023507852A (ja) 抗ｃ５抗体を使用して妊娠関連非典型溶血性尿毒症症候群を治療する方法
EA043233B1 (ru) ДОЗИРОВАНИЕ И ВВЕДЕНИЕ АНТИТЕЛ ПРОТИВ C5 ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ С ПАРОКСИЗМАЛЬНОЙ НОЧНОЙ ГЕМОГЛОБИНУРИЕЙ (PNH) И АТИПИЧНЫМ ГЕМОЛИТИКО-УРЕМИЧЕСКИМ СИНДРОМОМ (aHUS)
CN116836272A (zh) 一种抗鼠伤寒沙门氏菌鞭毛蛋白FlgE的驼源纳米抗体及其制备方法和应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190918

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210304

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210416